@article{M de Montalembert_V Brousse_C Elie_F Bernaudin_J Shi_P Landais_French Study Group on Sickle Cell Disease_2006, place={Pavia, Italy}, title={Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes}, volume={91}, url={https://haematologica.org/article/view/3809}, DOI={10.3324/%x}, abstractNote={Two hundred twenty-five SCD children have been enrolled in a study assessing the tolerability of hydroxyurea treatment. Mean age at inclusion was 9.2+/-4.4 years, median duration of treatment was 3.8 years. Ten and 75 patients have been treated respectively for more than 10 and 5 years. No severe side effect was related to hydroxyurea treatment, which was discontinued in 81 children mainly for treatment failure (30 cases) or non-compliance (17 cases). Treatment was also withdrawn in 5 of 6 children who had developed hypersplenism, in 3 because of a pathological transcranial Doppler, and in 2 after a stroke.}, number={1}, journal={Haematologica}, author={M de Montalembert and V Brousse and C Elie and F Bernaudin and J Shi and P Landais and French Study Group on Sickle Cell Disease}, year={2006}, month={Jan.}, pages={125-128} }